A range of genetic alterations in glioma brain cancers have been identified that could affect adult brain cancer patients’ responses to treatment and survival.
Dr Karisa Schreck, an assistant professor of neurology at Johns Hopkins University School of Medicine, Baltimore, USA, told the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, that although the different alterations in the BRAF gene were well understood in gliomas occurring in children, it was not in adults.
She and her colleagues collected data from Dana-Farber/Harvard Cancer Center, Johns Hopkins Hospital, the Project Genomics Evidence Neoplasia Information Exchange (GENIE) and The Cancer Genome Atlas (TCGA) on nearly 300 glioma patients, 206 of whom were adults.
They examined clinical information, including what treatments the patients received and how long they lived, and the structure and molecular make-up of tumour tissues, including genetic alterations.
They went on to divide the tumours into three groups, based on how the BRAF alteration activates the ERK signalling pathway that contributes to cancer: Class I (mutations such as BRAFv600E, in which BRAF is able to activate ERK by itself); Class II (mutations in which BRAF needs to pair up with another BRAF molecule to activate ERK in a process called dimerisation); Class III (mutations that amplify ERK signalling through the RAS gene and other signalling molecules); and also gene rearrangements, amplifications and other, unclassified alterations.
Dr Schreck found that BRAF-altered gliomas in adults and children had different features, with more Class I BRAFv600E alterations in adults, and more BRAF fusions in childhood glioma.
BRAFv600E alterations were associated with improved overall survival in adults with glioma, but for glioblastoma, the most aggressive type of glioma, there was no improvement and increased age was associated with worse survival in these patients.
The researchers also found that BRAFv600E conferred sensitivity to targeted therapy in adult patients and demonstrated there were other BRAF alterations in patients with glioma that might be targetable using MEK inhibitors or dimerisation-disrupting BRAF inhibitors.
Out of 13 patients, six patients had pleomorphic xanthoastrocytoma, four had glioblastoma multiforme, two had pilocytic astrocytoma and one had another type of astrocytoma and targeted therapies halted the growth or shrank the glioma in six of them.
The average time before the cancer progressed was five months and the overall survival time was nearly 14 years. It was four and a half years in patients with glioblastoma.

Leave a Reply